Salivary adenoid cystic carcinoma in Denmark 1990-2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Salivary adenoid cystic carcinoma in Denmark 1990-2005 : Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). / Bjørndal, Kristine; Krogdahl, Annelise; Therkildsen, Marianne H; Charabi, Birgitte; Kristensen, Claus A; Andersen, Elo; Schytte, Sten; Primdahl, Hanne; Johansen, Jørgen; Pedersen, Henrik B.; Andersen, Lisbeth J; Godballe, Christian.
In: Oral Oncology, Vol. 51, No. 12, 12.2015, p. 1138-42.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Salivary adenoid cystic carcinoma in Denmark 1990-2005
T2 - Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)
AU - Bjørndal, Kristine
AU - Krogdahl, Annelise
AU - Therkildsen, Marianne H
AU - Charabi, Birgitte
AU - Kristensen, Claus A
AU - Andersen, Elo
AU - Schytte, Sten
AU - Primdahl, Hanne
AU - Johansen, Jørgen
AU - Pedersen, Henrik B.
AU - Andersen, Lisbeth J
AU - Godballe, Christian
N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.
PY - 2015/12
Y1 - 2015/12
N2 - AIM: To describe outcome and prognostic factors, including the effect of radiotherapy, in a consecutive national series of salivary gland adenoid cystic carcinomas.METHODS: From the national Danish salivary gland carcinoma database in the structure of DAHANCA, 201 patients diagnosed with adenoid cystic carcinoma, and treated with a curative intent, were identified in the period between 1990 and 2005. Variables necessary for statistical analyses were extracted from the database.RESULTS: The 10-year crude survival and disease specific survival rates were 58% and 75%, respectively. The 10-year locoregional control rate was 70%, and 36% of patients experienced a recurrence during follow-up (median 7.5 years); 18% developed distant metastases (most commonly to the lungs). In multivariate analysis, stage and margin status were both important factors with regards to survival and locoregional control. Radiotherapy did not improve survival, but it did improve the locoregional control rate.CONCLUSIONS: The treatment of choice is surgery with as wide margins as possible including elective, selective neck dissection. Adjuvant radiotherapy should be considered in patients with incomplete tumor resection, high disease stages, and tumors with a solid growth pattern.
AB - AIM: To describe outcome and prognostic factors, including the effect of radiotherapy, in a consecutive national series of salivary gland adenoid cystic carcinomas.METHODS: From the national Danish salivary gland carcinoma database in the structure of DAHANCA, 201 patients diagnosed with adenoid cystic carcinoma, and treated with a curative intent, were identified in the period between 1990 and 2005. Variables necessary for statistical analyses were extracted from the database.RESULTS: The 10-year crude survival and disease specific survival rates were 58% and 75%, respectively. The 10-year locoregional control rate was 70%, and 36% of patients experienced a recurrence during follow-up (median 7.5 years); 18% developed distant metastases (most commonly to the lungs). In multivariate analysis, stage and margin status were both important factors with regards to survival and locoregional control. Radiotherapy did not improve survival, but it did improve the locoregional control rate.CONCLUSIONS: The treatment of choice is surgery with as wide margins as possible including elective, selective neck dissection. Adjuvant radiotherapy should be considered in patients with incomplete tumor resection, high disease stages, and tumors with a solid growth pattern.
U2 - 10.1016/j.oraloncology.2015.10.002
DO - 10.1016/j.oraloncology.2015.10.002
M3 - Journal article
C2 - 26476712
VL - 51
SP - 1138
EP - 1142
JO - Oral Oncology Extra
JF - Oral Oncology Extra
SN - 1741-9409
IS - 12
ER -
ID: 162751363